Sprint Bioscience (SPRINT) Q3 2025 earnings summary

Executive summary

• Sold TREX1 cancer program to Gilead Sciences post-period for $14M upfront and up to $400M in milestones, significantly strengthening financial position and validating research quality.

• Focus remains on advancing internal pipeline, expanding platform collaborations, and leveraging new partnerships for future growth.

Financial highlights

• Q3 net revenue was 5.2 MSEK, down from 14.8 MSEK year-over-year; nine-month revenue was 33.2 MSEK, down from 49.4 MSEK.

• Q3 operating loss was -8.4 MSEK (vs. -5.4 MSEK); nine-month operating loss was -20.2 MSEK (vs. -14.8 MSEK).

• Net loss for Q3 was -8.4 MSEK (vs. -5.2 MSEK); nine-month net loss was -21.4 MSEK (vs. -14.1 MSEK).

• Cash flow from operations for Q3 was -13.9 MSEK (vs. -4.3 MSEK); nine-month cash flow was -32.3 MSEK (vs. -17.2 MSEK).

• Cash at period end was 10.9 MSEK, down from 31.7 MSEK year-over-year.

Outlook and guidance

• No formal forecast provided; focus on leveraging strengthened financials and pipeline progress post-Gilead deal.